on this page
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with patisiran and vutrisiran under the National Health Act 1953, section 100 for adult patients with hereditary transthyretin amyloidosis.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing patisiran and vutrisiran.
Section 100 arrangements
Patisiran and vutrisiran
These items are only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:
- an approved private hospital
- a public hospital.
These items aren’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.
Treatment specifics
To be eligible for initial PBS-subsidised treatment with patisiran or vutrisiran, patients must be treated by, or in consultation with, a consultant with experience in the management of amyloid disorders.
Authority applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised patisiran or vutrisiran to treat hereditary transthyretin amyloidosis can be made in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed hereditary transthyretin amyloidosis - patisiran or vutrisiran - initial authority application form
- relevant attachments.
Applying for initial grandfather treatment
Applications for initial grandfather authority approval to prescribe PBS-subsidised patisiran or vutrisiran to treat hereditary transthyretin amyloidosis can be made in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed hereditary transthyretin amyloidosis - patisiran or vutrisiran - initial grandfather authority application form
- relevant attachments.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised patisiran or vutrisiran to treat hereditary transthyretin amyloidosis can be made in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed hereditary transthyretin amyloidosis - patisiran or vutrisiran - continuing authority application form
- relevant attachments.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.